ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

8609	Companies
141447	Keywords
77324	Articles
75565	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/10/2024 at 07:30, 7 months ago

OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petites cellules
OSE Immunotherapeutics lance l'étude internationale d'Artemia en Phase 3 pour Tedopi® contre le cancer du poumon non à petites cellules, aux États-Unis, Canada, Europe, Royaume-Uni, avec présentations aux conférences WCLC et ESMO

Phase 3 OSE Immunotherapeutics Vaccin Thérapeutique Tedopi Cancer Du Poumon Non À Petites Cellules
BRIEF

published on 07/01/2024 at 07:35, 9 months 9 days ago

OSE Immunotherapeutics Publishes Preclinical Efficacy Results for Lusvertikimab in ALL

Immunotherapy OSE Immunotherapeutics Preclinical Results Lusvertikimab Acute Lymphoblastic Leukemia
BRIEF

published on 07/01/2024 at 07:35, 9 months 9 days ago

OSE Immunotherapeutics publie les résultats précliniques d’efficacité du Lusvertikimab dans la LAL

Immunothérapie Lusvertikimab Leucémie Lymphoblastique Aiguë OSE Immunothérapie Résultats Précliniques
PRESS RELEASE

published on 07/01/2024 at 07:30, 9 months 9 days ago

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’
OSE Immunotherapeutics publie des résultats précliniques prometteurs sur Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans 'Blood', ouvrant de nouvelles perspectives en immunothérapie pour les patients atteints de LAL

Immunothérapie Publication OSE Immunotherapeutics Lusvertikimab Leucémie Aiguë Lymphoblastique
PRESS RELEASE

published on 07/01/2024 at 07:30, 9 months 9 days ago

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics announces publication of preclinical efficacy results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'. Collaboration with University Medical Center Schleswig-Holstein on targeting ALL patients

OSE Immunotherapeutics Lusvertikimab Acute Lymphoblastic Leukemia Blood Journal IL-7 Receptor Antagonist
BRIEF

published on 06/24/2024 at 07:35, 9 months 16 days ago

OSE Immunotherapeutics signe un accord stratégique avec MSK pour les thérapies par cellules CAR-T

OSE Immunotherapeutics Leucémie Memorial Sloan Kettering Cancer Center CAR-T IL-7R
BRIEF

published on 06/24/2024 at 07:35, 9 months 16 days ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 9 months 16 days ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
PRESS RELEASE

published on 06/24/2024 at 07:30, 9 months 16 days ago

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R

Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
BRIEF

published on 06/20/2024 at 07:35, 9 months 20 days ago

OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA

Accesswire

Published on 04/10/2025 at 15:15, 48 minutes ago

ReelTime’s Reel Intelligence "RI" Outperforms AI While Requiring a Fraction of The Resources
Published on 04/10/2025 at 15:00, 1 hour 3 minutes ago

Route1 Signs Significant New Orders with Major Cities in the Southwestern United States and Announces Key Corporate Updates Including Its Acquisition Growth Strategy
Published on 04/10/2025 at 15:00, 1 hour 3 minutes ago

Inspire Veterinary Partners Announces Attendance at Upcoming Investor Events
Published on 04/10/2025 at 15:00, 1 hour 3 minutes ago

Xebra Brands Launches National RFP to Establish Cannabis Cultivation Partnerships Across Mexico
Published on 04/10/2025 at 14:30, 1 hour 33 minutes ago

CCL to Hold Live Webcast Call to Discuss 2025 First Quarter Results, Thursday, May 8, 2025, at 7:30 a.m. ET

View all ACCESSWIRE

EQS Group

Published on 04/10/2025 at 15:40, 22 minutes ago

Financing commitment: American West secures long-term future of the Storm copper project!
Published on 04/10/2025 at 15:30, 32 minutes ago

Siegfried shareholders approve all proposals at Annual General Meeting 2025
Published on 04/10/2025 at 15:00, 1 hour 2 minutes ago

Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
Published on 04/10/2025 at 13:50, 2 hours 12 minutes ago

Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use
Published on 04/10/2025 at 13:12, 2 hours 50 minutes ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Les Echos

Published on 04/09/2025 at 18:59, 21 hours 3 minutes ago

Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:59, 21 hours 3 minutes ago

Descriptif du programme de rachat d'actions 2025-2026
Published on 04/09/2025 at 18:57, 21 hours 5 minutes ago

Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 18:57, 21 hours 5 minutes ago

Compte-rendu de l'Assemblée Générale Mixte du 9 avril 2025
Published on 04/09/2025 at 17:45, 22 hours 18 minutes ago

COGELEC : Résultats annuels 2024 et Chiffre d’affaires du 1 er trimestre 2025.

View all LES ECHOS COMFI WIRE